Agenus (NASDAQ:AGEN) Cut to Sell at BidaskClub

Share on StockTwits

Agenus (NASDAQ:AGEN) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Wednesday, BidAskClub reports.

Several other brokerages have also recently commented on AGEN. B. Riley started coverage on shares of Agenus in a research report on Friday, December 20th. They set a “buy” rating and a $6.00 price target on the stock. ValuEngine raised shares of Agenus from a “hold” rating to a “buy” rating in a research report on Saturday, January 18th.

Shares of NASDAQ:AGEN opened at $3.71 on Wednesday. The company’s 50-day moving average price is $3.87 and its two-hundred day moving average price is $3.19. Agenus has a one year low of $2.13 and a one year high of $4.57. The stock has a market capitalization of $519.23 million, a PE ratio of -3.74 and a beta of 2.09.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.05. The business had revenue of $19.94 million for the quarter, compared to the consensus estimate of $15.60 million. As a group, research analysts expect that Agenus will post -0.97 EPS for the current year.

A number of large investors have recently modified their holdings of the business. BlackRock Inc. lifted its position in Agenus by 11.0% during the 2nd quarter. BlackRock Inc. now owns 9,294,627 shares of the biotechnology company’s stock worth $27,884,000 after buying an additional 919,105 shares in the last quarter. Vanguard Group Inc. lifted its position in Agenus by 16.7% during the 2nd quarter. Vanguard Group Inc. now owns 5,540,211 shares of the biotechnology company’s stock worth $16,620,000 after buying an additional 793,180 shares in the last quarter. State Street Corp lifted its position in Agenus by 14.8% during the 3rd quarter. State Street Corp now owns 2,399,958 shares of the biotechnology company’s stock worth $6,192,000 after buying an additional 309,954 shares in the last quarter. Northern Trust Corp lifted its position in Agenus by 0.9% during the 2nd quarter. Northern Trust Corp now owns 1,167,016 shares of the biotechnology company’s stock worth $3,501,000 after buying an additional 10,663 shares in the last quarter. Finally, Millennium Management LLC lifted its position in Agenus by 68.8% during the 3rd quarter. Millennium Management LLC now owns 750,487 shares of the biotechnology company’s stock worth $1,936,000 after buying an additional 305,807 shares in the last quarter. 35.68% of the stock is currently owned by hedge funds and other institutional investors.

About Agenus

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

See Also: How Do I Invest in Dividend Stocks

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

HBT Financial  Given Average Rating of “Buy” by Analysts
HBT Financial Given Average Rating of “Buy” by Analysts
Drexel Morgan & Co. Has $1.63 Million Stock Holdings in Caterpillar Inc.
Drexel Morgan & Co. Has $1.63 Million Stock Holdings in Caterpillar Inc.
Medtronic PLC  Shares Sold by Drexel Morgan & Co.
Medtronic PLC Shares Sold by Drexel Morgan & Co.
Drexel Morgan & Co. Reduces Stock Holdings in Walt Disney Co
Drexel Morgan & Co. Reduces Stock Holdings in Walt Disney Co
Drexel Morgan & Co. Reduces Holdings in Deere & Company
Drexel Morgan & Co. Reduces Holdings in Deere & Company
Analysts Anticipate China Yuchai International Limited  to Post $0.32 Earnings Per Share
Analysts Anticipate China Yuchai International Limited to Post $0.32 Earnings Per Share


© 2006-2020 Ticker Report